Septerna, Inc. (NASDAQ:SEPN) Receives Average Rating of “Moderate Buy” from Analysts

Septerna, Inc. (NASDAQ:SEPN) has earned a consensus recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $45.8889.

SEPN has been the topic of a number of research reports. Truist Financial lifted their price target on shares of Septerna from $35.00 to $43.00 and gave the company a “buy” rating in a research note on Wednesday. Wall Street Zen lowered shares of Septerna from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research report on Tuesday, April 21st. Stifel Nicolaus began coverage on shares of Septerna in a research report on Friday, May 1st. They issued a “buy” rating and a $43.00 price objective on the stock. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $40.00 target price on shares of Septerna in a research note on Wednesday.

Insider Activity

In related news, SVP Daniel D. Long sold 3,333 shares of Septerna stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $34.36, for a total value of $114,521.88. Following the sale, the senior vice president owned 96,412 shares of the company’s stock, valued at approximately $3,312,716.32. This trade represents a 3.34% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Elizabeth Bhatt sold 4,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 15th. The shares were sold at an average price of $24.34, for a total value of $97,360.00. Following the completion of the sale, the chief operating officer owned 174,209 shares in the company, valued at $4,240,247.06. The trade was a 2.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 48,494 shares of company stock worth $1,566,751 over the last three months. Corporate insiders own 5.80% of the company’s stock.

Hedge Funds Weigh In On Septerna

Large investors have recently bought and sold shares of the company. Avoro Capital Advisors LLC lifted its position in shares of Septerna by 8.1% in the third quarter. Avoro Capital Advisors LLC now owns 1,337,500 shares of the company’s stock worth $25,158,000 after purchasing an additional 100,000 shares in the last quarter. New York State Common Retirement Fund grew its position in Septerna by 93.1% in the fourth quarter. New York State Common Retirement Fund now owns 5,600 shares of the company’s stock valued at $156,000 after purchasing an additional 2,700 shares in the last quarter. CW Advisors LLC bought a new position in Septerna in the second quarter valued at $133,000. Caitong International Asset Management Co. Ltd bought a new position in Septerna in the fourth quarter valued at $53,000. Finally, Global Retirement Partners LLC acquired a new stake in Septerna in the 4th quarter valued at $35,000.

Septerna Price Performance

NASDAQ SEPN opened at $34.00 on Friday. Septerna has a one year low of $10.62 and a one year high of $37.99. The firm has a market cap of $1.53 billion, a P/E ratio of -41.97 and a beta of 2.28. The stock’s 50-day moving average is $29.90 and its 200-day moving average is $27.61.

Septerna (NASDAQ:SEPN) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.23. Septerna had a negative return on equity of 12.72% and a negative net margin of 49.88%.The business had revenue of $26.52 million during the quarter, compared to analyst estimates of $16.98 million. Equities analysts anticipate that Septerna will post -1.59 EPS for the current year.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.